MedTrace Logo

Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)

NCT03931161 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2022-10-13

No results posted yet for this study

Summary

This is a phase IV, randomised, placebo-controlled, double-blind, parallel group study to determine the effect of Evolocumab treatment on carotid plaque morphology and composition in asymptomatic patients with \>50% carotid artery stenosis.

Conditions

  • Carotid Artery Stenosis

Interventions

DRUG

Evolocumab Auto-Injector [Repatha]

Auto-Injector, 140 mg every two weeks.

DRUG

Placebo Auto-Injector

Matching Placebo for the active comparator (Evolocumab)

Sponsors & Collaborators

  • Imperial College London

    collaborator OTHER

  • Imperial College Healthcare NHS Trust

    lead OTHER

Principal Investigators

  • Jaimini Cegla, BSc MSc MBBS MRCP FRCPath PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-04
Primary Completion
2023-05-06
Completion
2024-05-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03931161 on ClinicalTrials.gov